Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ZYTIGA is substantial. |
Clinical Added Value
| moderate |
ZYTIGA provides a moderate improvement in actual benefit (level III) in terms of efficacy and tolerance in the treatment of metastatic castration-resistant prostate cancer which progresses during or after docetaxel therapy. |
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
EuEAprNGCzsDWATb
Listen
